PDT Partners LLC Invests $244,000 in 2seventy bio, Inc. (NASDAQ:TSVT)

PDT Partners LLC purchased a new position in shares of 2seventy bio, Inc. (NASDAQ:TSVT) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 51,713 shares of the company’s stock, valued at approximately $244,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. SkyView Investment Advisors LLC grew its position in 2seventy bio by 25.0% during the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after buying an additional 2,500 shares during the period. Price T Rowe Associates Inc. MD grew its position in 2seventy bio by 11.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 28,929 shares of the company’s stock worth $155,000 after buying an additional 2,893 shares during the period. BBR Partners LLC grew its position in 2seventy bio by 66.7% during the second quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock worth $96,000 after buying an additional 10,000 shares during the period. Bank of New York Mellon Corp grew its position in 2seventy bio by 5.4% during the second quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company’s stock worth $758,000 after buying an additional 10,077 shares during the period. Finally, American Century Companies Inc. grew its position in 2seventy bio by 16.6% during the second quarter. American Century Companies Inc. now owns 79,953 shares of the company’s stock worth $308,000 after buying an additional 11,363 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

2seventy bio Trading Down 5.0 %

Shares of TSVT opened at $3.78 on Wednesday. The firm’s 50-day moving average is $4.46 and its two-hundred day moving average is $4.40. 2seventy bio, Inc. has a twelve month low of $1.92 and a twelve month high of $6.40. The firm has a market capitalization of $195.01 million, a P/E ratio of -2.03 and a beta of 1.69.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.